Skip to content

Benefits and Risks of Artificial Light Exposure: Characterisation of Effects on Alertness, Sleep, Cognitive Performance, Mood and Biological Rhythms

Benefits and Risks of Artificial Light Exposure: Characterisation of Effects on Alertness, Sleep, Cognitive Performance, Mood and Biological Rhythms

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05232383
Acronym
LumEnColor
Enrollment
96
Registered
2022-02-09
Start date
2021-12-02
Completion date
2026-05-01
Last updated
2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Sleep and Chronobiology

Brief summary

The purpose of this project is to study the influence of light on sleep, wakefulness, EEG activity and cognitive performances.

Interventions

DEVICEpolychromatic light

Application of polychromatic light at different times of day

DEVICEred light

Application of red light at different times of day

Application of green light at different times of day

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or female * Aged 18 to 40 years * With a hint of Bodymass index (BMI) between 17 and 30 kg.m - 2 * healthy subject determined by a clinical examination, a psychological interview, a blood test, a urine analysis * Subject with a score\<6 questionnaire PSQI (Sleep Questionnaire Pittsburgh) * Subject agreeing to maintain a regular sleep/wake rhythm during the study * Subject agreeing to refrain from caffeine, nicotine, alcohol, psychotropic drugs, cannabis or other drugs, during the study * Signed informed consent * Subjectaffiliated to a social protection scheme

Exclusion criteria

* somatic diseases: cardiovascular, respiratory, gastrointestinal, hematopoietic, Visual * immune system diseases * kidneys and urinary tract diseases * endocrine and metabolic diseases * neurological diseases * infectious diseases * thrombocytopenia or other malfunction of blood platelets * Subject with risk of thrombosis, including subject with a history of phlebitis, smoker under oral contraceptive... * Subject with an addiction to caffeine, nicotine, alcohol, psychotropic drugs, cannabis, or any other drug * Subject treatment contraindicated or inadvisable in combination with heparin * blood donation in the previous 3 months before the inclusion * Participation in other clinical trials * Work by shifts in the year preceding the inclusion * Trans-meridian travel (\> 2 time zones) in the month previous the inclusion * Impossibility to give enlightened information (subject in an emergency situation, understanding difficulties,...) * Subject under safeguard of justice * Subject under tutorship or curatorship * Pregnancy (women of childbearing age) * Breastfeeding * Diet incompatible with the study's snack choices

Design outcomes

Primary

MeasureTime frameDescription
Cognitive performances assessed using N-back tasksup to 56 hoursN-Back-Task 1, 2, 3
Cognitive performances assessed using Psychomotor Vigilance task (PVT)up to 56 hoursPsychomotor Vigilance task (PVT)
Cognitive performances assessed using Paced Visual Serial Addition Task (PVSAT)up to 56 hoursPaced Visual Serial Addition Task (PVSAT)

Countries

France

Contacts

Primary ContactPatrice BOURGIN, MD
pbourgin@unistra.fr03 88 11 64 30

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026